Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
SP Group is a Danish plastic manufacturer that produces moulded items in plastics and plastic composites and performs surface coatings on metal items. The company is listed on the Nasdaq OMX Copenhagen Stock Exchange. It dates back to 1972 and is headquartered in Denmark.
SP Group is a leading supplier of plastic-manufactured products to Danish industries. It services its clients through its factories in Denmark, Sweden, China, the USA, and Eastern Europe and its products are sold and marketed in around 90 countries.
The Company offers a number of collective competencies through its different plastics processing plants which create synergy both internally among the plants and externally in partnerships with customers.
The largest customer groups in terms of revenue are Healthcare, Cleantech, Food-related and Automotive, which adds up to around 75% of sales.
SP Group is part of the OMX Copenhagen Mid Cap Index.
Today, we publish our updated SP Group investment case following the Q2 2026 report. SP Group delivered its third consecutive record quarter, with Q2 revenue up 44.6% (29.4% organic) and guidance raised twice in six weeks to 24–30% growth, while the H1 EBITDA margin held at 20.3%. With consensus pointing to DKK 4.26bn revenue in 2027, the 2030 ambition of DKK 4.5bn looks attainable already in 2028, and the 2030 targets look set to be revisited.
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
SP Group is set to release their quarterly report for Q2 2026 on Thursday 20 August 2026. On Friday 21 August 2026 at 3:00 PM, CEO Lars Bering and CFO Allan Jeppesen will present the results and answer questions from the audience during an online live event.
SP Group ventes at offentliggøre sit regnskab for 2. kvartal 2026, og dermed 1. halvår 2026 – torsdag d. 20. august 2026. Dagen efter – fredag d. 21. august kl. 12.00 - kan du høre ledelsens udlægning af hvordan første halvdel af 2026 er forløbet for SP Group, når vi har CEO Lars Bering og CFO Allan Jeppesen igennem på et virtuelt event.
Udsigt til en flad til svag positiv åbning i Europa. Scott Bessent redningsplan holdt ikke længe Fokus på regnskabsaktuelle Better Collective, Bavarian. Gæst i studiet her til morgen er BioPorto CFO Klaus Juhl Wulff.
Rekord på både omsætning og indtjening hos SP Group, som opjusterer for anden gang i år på ryggen af et britisk opkøb, North Media leverer sit endelige Q2-regnskab få dage efter en nedjustering af helåret, og vi løfter sløret for vores allerførste investeringscase på nyligt børsnoterede BioMar.
I dag afholder vi fem online investorevents. Kl. 10:00 præsenterer Ascelia Pharma CEO Magnus Corfitzen resultaterne for Q2 2026. Kl. 11:00 præsenterer Lundbeck Jens Høyer, Vice President & Head of Investor Relations, halvårsrapporten for H1 2026. Kl. 12:00 præsenterer SP Group CEO Lars Bering og CFO Allan Jeppesen regnskabet for 2. kvartal 2026. Kl. 13:00 præsenterer WindowMaster CEO Erik Boyter og CFO Steen Overgaard Sørensen halvårsrapporten for H1 2026. Kl. 14:00 gennemgår North Medias ledelse regnskabet for 2. kvartal 2026. Tilmeld dig og stil dine spørgsmål allerede nu.
SP Group released its Q2 2026 report this morning, covering the first half of 2026, and reported record sales and earnings. At the same time, the sales guidance for 2026 has been raised for the second time this year, this time following the acquisition of OGM Moulding Ltd. in the UK, which was announced yesterday.
SP Group køber britiske OGM Moulding for ca. DKK 158 mio. og opjusterer omsætningsforventningerne til 2026.
GrønlandsBANKEN leverer solid fremgang på bundlinjen i H1 med et stærkt Q2, der opvejer en svagere start på året.
GreenMobility lander flerårig ladeaftale med EDF, hvor franskmændene tager hele investeringen og driftsomkostningerne.
Ascelia Pharma halverer driftsunderskuddet i Q2 og har kapital ind i Q2 2027 frem mod FDA-mødet den 9. september.
Gubra melder om stærkt klinisk pipeline-momentum, og CRO-forretningen viser tegn på at have fundet bunden.
BioPorto ser underliggende NGAL-vækst på 23% og tilføjer seks nye amerikanske hospitaler, mens 2026-guidance fastholdes.
ALK-Abelló slår konsensus på både top- og bundlinje i Q2 og løfter bunden af omsætningsguidancen for 2026.
ExpreS2ion Biotech rapporterer HER2-antistofrespons hos 12 ud af 13 evaluerbare patienter og ingen dosisbegrænsende toksicitet.